Restless Legs Syndrome and Periodic Leg Movements of Sleep

Neurologic Clinics

Volumn 30, Issue 4, 2012, Pages 1137-1166

  Rye, David B ^a   Trotti, Lynn Marie ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Flexor withdrawal; Iron; Periodic leg movements; Restless legs; Supraspinal

Indexed keywords

ANTIDEPRESSANT AGENT; CABERGOLINE; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPHEDRINE; FERRIC GLUCONATE; GABAPENTIN; IRON; IRON DERIVATIVE; IRON DEXTRAN; IRON SACCHARATE; LEVODOPA; LITHIUM; MECLOZINE; METOCLOPRAMIDE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OPIATE DERIVATIVE; PRAMIPEXOLE; PREGABALIN; PROTON PUMP INHIBITOR; PSEUDOEPHEDRINE; ROPINIROLE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ANAPHYLAXIS; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EUROPE; GENDER; HEADACHE; HUMAN; INSOMNIA; IRON DEFICIENCY; IRON STORAGE; MYOCLONUS; NAUSEA; PATHOPHYSIOLOGY; PERIODIC LIMB MOVEMENT DISORDER; PERIPHERAL EDEMA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RESTLESS LEGS SYNDROME; REVIEW; RHINITIS; RISK FACTOR; SENSORIMOTOR CORTEX; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DOPAMINE AGONISTS; FEMALE; HUMANS; LEG; MALE; MOVEMENT; RESTLESS LEGS SYNDROME; SEX CHARACTERISTICS; SLEEP;

EID: 84867913961     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2012.08.004     Document Type: Review

References (251)

1. Allen R., Hening W., Montplaisir J., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the RLS diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
2. Stefansson H., Rye D.B., Hicks A., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007, 357(7):639-647. [see comment].
3. Hening W.A. Subjective and objective criteria in the diagnosis of the restless legs syndrome. Sleep Med 2004, 5(3):285-292.
4. Hening W.A., Allen R.P., Washburn M., et al. The four diagnostic criteria for restless legs syndrome are unable to exclude confounding conditions (" mimics" ). Sleep Med 2009, 10(9):976-981.
5. Benes H., Walters A.S., Allen R.P., et al. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 2007, 22(Suppl 18):S401-S408.
6. Chaudhuri K.R., Rye D.B., Muzerengi S. Differential diagnosis of RLS. Restless legs syndrome 2008, 35-43. Oxford University Press, Oxford (United Kingdom). K.R. Chaudhuri, L. Ferini-Strambi, D.B. Rye (Eds.).
7. Spillane J.D., Nathan P.W., Kelly R.E., et al. Painful legs and moving toes. Brain 1971, 94(3):541-556.
8. Dressler D., Thompson P.D., Gledhill R.F., et al. The syndrome of painful legs and moving toes. Mov Disord 1994, 9(1):13-21.
9. Hening W., Walters A., Allen R., et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004, 5:237-246.
10. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165(11):1286-1292.
11. Michaud M., Dumont M., Selmaoui B., et al. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 2004, 55:372-380.
12. Duffy J., Lowe A., Winkelman J., et al. Peak circadian occurrence of PLMs during the biological nighttime. Sleep 2005, 28(Suppl):A275. [abstract].
13. Baier P., Trenkwalder C. Circadian variation in restless legs syndrome. Sleep Med 2007, 8(6):645-650.
14. Picchietti D., Stevens H. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2007, 22:297-300.
15. Phillips B., Young T., Finn L., et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000, 160:2137-2141.
16. Trotti L.M., Bliwise D., Greer S.A., et al. Correlates of PLMs variability over multiple nights and impact upon RLS diagnosis. Sleep Med 2009, 10(6):668-671.
17. Lamberg L. Sleeping poorly while pregnant may not be "normal". JAMA 2006, 295(12):1357-1361.
18. Manconi M., Govoni V., De Vito A., et al. Restless legs syndrome and pregnancy. Neurology 2004, 63:1065-1069.
19. Berger K., Luedemann J., Trenkwalder C., et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004, 164:196-202.
20. Desai A., Cherkas L., Spector T., et al. Genetic influences in self-reported symptoms of obstructive sleep apnoea and restless legs syndrome: a twin study. Twin Res 2004, 7:589-595.
21. Ondo W.G., Vuong K.D., Wang Q. Restless legs syndrome in monozygotic twins. Neurology 2000, 55(9):1404-1406.
22. Tan E., Seah A., See S., et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001, 16:577-579.
23. Cho S.J., Hong J.P., Hahm B.J., et al. Restless legs syndrome in a community sample of Korean adults: prevalence, impact on quality of life, and association with DSM-IV psychiatric disorders. Sleep 2009, 32(8):1069-1076.
24. Castillo P.R., Kaplan J., Lin S.C., et al. Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin Proc 2006, 81(10):1345-1347.
25. Sevim S., Dogu O., Camdeviren H., et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003, 61(11):1562-1569.
26. Inoue Y., Ishizuka T., Arai H. Surveillance on epidemiology and treatment of restless legs syndrome in Japan. J New Rem Clim 2000, 49:244-254.
27. Earley C., Allen R., Beard J., et al. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000, 62(5):623-628.
28. Silber M., Richardson J. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 2003, 78:52-54.
29. Winkelman J.W., Chertow G.M., Lazarus J.M. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996, 28(3):372-378.
30. Hening W.A., Caivano C.K. Restless legs syndrome: a common disorder in patients with rheumatologic conditions. Semin Arthritis Rheum 2008, 38(1):55-62.
31. Merlino G., Fratticci L., Valente M., et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007, 30(7):866-871.
32. Minai O.A., Malik N., Foldvary N., et al. Prevalence and characteristics of restless legs syndrome in patients with pulmonary hypertension. J Heart Lung Transplant 2008, 27(3):335-340.
33. Kaplan Y., Inonu H., Yilmaz A., et al. Restless legs syndrome in patients with chronic obstructive pulmonary disease. Can J Neurol Sci 2008, 35(3):352-357.
34. Lo Coco D., Mattaliano A., Lo Coco A., et al. Increased frequency of restless legs syndrome in chronic obstructive pulmonary disease patients. Sleep Med 2009, 10(5):572-576.
35. Benediksdottir B., Arnardottir E., Janson C., et al. Prevalence of restless legs syndrome among patients with obstructive sleep apnea before and after CPAP treatment, compared to the general population-the Icelandic Sleep Apnea Cohort (ISAC) study. Sleep 2012, 35:A265.
36. Franco R.A., Ashwathnarayan R., Deshpandee A., et al. The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice. J Clin Sleep Med 2008, 4(1):45-49.
37. Weinstock L.B., Bosworth B.P., Scherl E.J., et al. Crohn's disease is associated with restless legs syndrome. Inflamm Bowel Dis 2009, 16(2):275-279.
38. Manchanda S., Davies C.R., Picchietti D. Celiac disease as a possible cause for low serum ferritin in patients with restless legs syndrome. Sleep Med 2009, 10(7):763-765.
39. Weinstock L.B., Walters A.S., Mullin G.E., et al. Celiac disease is associated with restless legs syndrome. Dig Dis Sci 2009, 55(6):1667-1673.
40. Banerji N.K., Hurwitz L.J. Restless legs syndrome, with particular reference to its occurrence after gastric surgery. Br Med J 1970, 4(5738):774-775.
41. Weinstock L.B., Fern S.E., Duntley S.P. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 2008, 53(5):1252-1256.
42. Cologno D., Cicarelli G., Petretta V., et al. High prevalence of dopaminergic premonitory symptoms in migraine patients with restless legs syndrome: a pathogenetic link?. Neurol Sci 2008, 29(Suppl 1):S166-S168.
43. Rhode A.M., Hosing V.G., Happe S., et al. Comorbidity of migraine and restless legs syndrome-a case-control study. Cephalalgia 2007, 27(11):1255-1260.
44. Poewe W., Hogl B. Akathisia, restless legs, and periodic limb movements in sleep in Parkinson's disease. Neurology 2004, 63(Suppl 3):S12-S16.
45. Nomura T., Inoue Y., Miyake M., et al. Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord 2006, 21(3):380-384.
46. Gomez-Esteban J.C., Zarranz J.J., Tijero B., et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2007, 22(13):1912-1916.
47. Calzetti S., Negrotti A., Bonavina G., et al. Absence of comorbidity of Parkinson disease and restless legs syndrome: a case-control study in patients attending a movement disorders clinic. Neurol Sci 2009, 30:119-122.
48. Lee J., Shin H., Kim K., et al. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord 2009, 24(4):579-582.
49. Trotti L.M., Rye D.B. Functional anatomy and treatment of RLS/PLMS emerging after spinal cord lesions. Sleep 2007, 30:A306.
50. Abele M., Burk K., Laccone F., et al. Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. J Neurol 2001, 248(4):311-314.
51. Schöls L., Haan J., Riess O., et al. Sleep disturbance in spinocerebellar ataxias. Is the SCA3 mutation a cause of restless leg syndrome?. Neurology 1998, 51:1603-1607.
52. Tuin I., Voss U., Kang J.S., et al. Stages of sleep pathology in spinocerebellar ataxia type 2 (SCA2). Neurology 2006, 67(11):1966-1972.
53. Manconi M., Fabbrini M., Bonanni E., et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007, 14(5):534-539.
54. Winkelmann J., Polo O., Provini F., et al. Genetics of restless legs syndrome (RLS): state-of-the-art and future directions. Mov Disord 2007, 22(Suppl 18):S449-S458.
55. Winkelmann J., Lichtner P., Schormair B., et al. Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord 2008, 23(3):350-358.
56. Winkelmann J., Schormair B., Lichtner P., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007, 39(8):1000-1006. [see comment].
57. Vilarino-Guell C., Farrer M.J., Lin S.C. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2008, 358(4):425-427.
58. Schormair B., Kemlink D., Roeske D., et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008, 40(8):946-948.
59. Winkelmann J., Czamara D., Schormair B., et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 2011, 7(7):e1002171.
60. Mignot E. A step forward for restless legs syndrome. Nat Genet 2007, 39(8):938-939. [comment].
61. Catoire H., Dion P.A., Xiong L., et al. Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Ann Neurol 2011, 70(1):170-175.
62. Freeman A., Pranski E., Miller R.D., et al. Sleep fragmentation and motor restlessness in a Drosophila model of restless legs syndrome. Curr Biol 2012, 22(12):1142-1148.
63. Bara-Jimenez W., Aksu M., Graham B., et al. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 2000, 54(8):1609-1616.
64. Aksu M., Bara-Jimenez W. State dependent excitability changes of spinal flexor reflex in patients with restless legs syndrome secondary to chronic renal failure. Sleep Med 2002, 3(5):427-430.
65. Rijsman R.M., Stam C.J., de Weerd A.W. Abnormal H-reflexes in periodic limb movement disorder; impact on understanding the pathophysiology of the disorder. Clin Neurophysiol 2005, 116(1):204-210.
66. Clemens S., Hochman S. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 2004, 24:11337-11345.
67. Clemens S., Rye D., Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006, 67(1):125-130.
68. Jakobsson B., Ruuth K. Successful treatment of restless legs syndrome with an implanted pump for intrathecal drug delivery. Acta Anaesthesiol Scand 2002, 46(1):114-117.
69. Lindvall P., Ruuth K., Jakobsson B., et al. Intrathecal morphine as a treatment for refractory restless legs syndrome. Neurosurgery 2008, 63(6):E1209. [author reply: E1209].
70. Ross D.A., Narus M.S., Nutt J.G. Control of medically refractory restless legs syndrome with intrathecal morphine: case report. Neurosurgery 2008, 62(1):E263. [discussion: E263].
71. Yokota T., Hirose K., Tanabe H., et al. Sleep-related periodic leg movements (nocturnal myoclonus) due to spinal cord lesion. J Neurol Sci 1991, 104:13-18.
72. Dickel M., Renfrow S., Moore P., et al. Rapid eye movement sleep periodic leg movements in patients with spinal cord injury. Sleep 1994, 17(8):733-738.
73. Lee M., Choi Y., Lee S. Sleep-related periodic leg movements associated with spinal cord lesions. Mov Disord 1996, 11(6):719-722.
74. de Mello M., Lauro F., Silva A., et al. Incidence of periodic leg movements and of the restless legs syndrome during sleep following acute physical activity in spinal cord injury subjects. Spinal Cord 1996, 34(5):294-296.
75. Manconi M., Rocca M., Ferini-Strambi L., et al. Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler 2008, 14(1):86-93.
76. Rutkove S., Matheson J., Logigian E. Restless legs syndrome in patients with polyneuropathy. Muscle Nerve 1996, 19(5):670-672.
77. Ondo W., Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996, 47:1435-1441.
78. Gemignani F., Marbini A., Di Giovanni G., et al. Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Neurology 1999, 52(5):1064-1066. [see comment].
79. Hattan E., Chalk C., Postuma R. Is there a higher risk of restless legs syndrome in peripheral neuropathy?. Neurology 2009, 72(11):955-960.
80. Iannaccone S., Zucconi M., Marchettini P., et al. Evidence of peripheral axonal neuropathy in primary restless legs syndrome. Mov Disord 1995, 10(1):2-9.
81. Polydefkis M., Allen R., Hauer P., et al. Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology 2000, 55(8):1115-1121.
82. Montplaisir J., Godbout R., Boghen D., et al. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985, 35:130-134.
83. Provini F., Vetrugno R., Meletti S., et al. Motor pattern of periodic limb movements during sleep. Neurology 2001, 57(2):300-304.
84. Ferreri F., Rossini P. Neurophysiological investigations in restless legs syndrome and other disorders of movement during sleep. Sleep Med 2004, 5:397-399.
85. Tyvaert L., Laureau E., Hurtevent J., et al. A-delta and C-fibres function in primary restless legs syndrome. Neurophysiol Clin 2009, 39(6):267-274.
86. Wechsler L., Stakes J., Shahani B., et al. Periodic leg movements of sleep (nocturnal myoclonus): an electrophysiological study. Ann Neurol 1986, 19:168-173.
87. Smith R., Gouin P., Minkley P., et al. Periodic limb movement disorder is associated with normal motor conduction latencies when studied by central magnetic stimulation-successful use of a new technique. Sleep 1992, 15(4):312-318.
88. Garcia-Borreguero D., Larrosa O., de la Llave Y., et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002, 59:1573-1579.
89. Ekbom K. Restless legs. Acta Med Scand Suppl 1945, 158:1-123.
90. Wechsler L., Stakes J., Shahani B., et al. Nocturnal myoclonus, restless legs syndrome, and abnormal electrophysiological findings. Ann Neurol 1987, 21:515.
91. Briellmann R., Rosler K., Hess C. Blink reflex excitability is abnormal in patients with periodic leg movements in sleep. Mov Disord 1996, 11(6):710-714.
92. Scalise A., Cadore I.P., Gigli G.L. Motor cortex excitability in restless legs syndrome. Sleep Med 2004, 5(4):393-396.
93. Nardone R., Ausserer H., Bratti A., et al. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurol Scand 2006, 114(4):244-249.
94. Fleetwood-Walker S., Hope P., Mitchell R. Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J Physiol (Lond) 1988, 399:335-348.
95. Garraway S., Hochman S. Modulatory actions of serotonin, norepinephrine, dopamine, and acetylcholine in spinal cord deep dorsal horn neurons. J Neurophysiol 2001, 86:2183-2194.
96. Millan M.J., Colpaert F.C. alpha2 Receptors mediate the antinociceptive action of 8-OH-DPAT in the hot-plate test in mice. Brain Res 1991, 539:342-346.
97. Yoshimura M., Furue H. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci 2006, 101(2):107-117.
98. Wei H., Viisanen H., Pertovaara A. Descending modulation of neuropathic hypersensitivity by dopamine D2 receptors in or adjacent to the hypothalamic A11 cell group. Pharmacol Res 2009, 59(5):355-363.
99. Ondo W.G., He Y., Rajasekaran S., et al. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 2000, 15(1):154-158.
100. Qu S., Le W., Zhang X., et al. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 2007, 66(5):383-388.
101. Zhao H., Zhu W., Pan T., et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res 2007, 85(5):1065-1076.
102. Stiasny-Kolster K., Magerl W., Oertel W., et al. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 2004, 127:773-782.
103. Han J.K., Oh K., Kim B.J., et al. Cutaneous silent period in patients with restless leg syndrome. Clin Neurophysiol 2007, 118(8):1705-1710.
104. Rye D., Freeman A. Pain and its interaction with thalamocortical excitability states. Sleep and pain 2007, 77-97. IASP Press, Seattle (WA). G. Lavigne, M. Choinière, B. Sessle (Eds.).
105. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008, 8(5):781-797.
106. Rye D., DeLong M. Amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy. Ann Neurol 1999, 46(5):800-801.
107. Kedia S., Moro E., Tagliati M., et al. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 2004, 63(12):2410-2412.
108. Driver-Dunckley E., Evidente V.G., Adler C.H., et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 2006, 21(8):1287-1289.
109. Ondo W. VIM deep brain stimulation does not improve pre-existing restless legs syndrome in patients with essential tremor. Parkinsonism Relat Disord 2006, 12(2):113-114.
110. Lee S.J., Kim J.S., Song I.U., et al. Poststroke restless legs syndrome and lesion location: anatomical considerations. Mov Disord 2009, 24(1):77-84.
111. Ferini-Strambi L., Filippi M., Martinelli V., et al. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci 1994, 125:194-197.
112. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004, 5(4):385-391.
113. Allen R., Earley C. The role of iron in restless legs syndrome. Mov Disord 2007, 22(Suppl 18):S440-S448.
114. Connor J. Pathophysiology of restless legs syndrome: evidence for iron involvement. Curr Neurol Neurosci Rep 2008, 8(2):162-166.
115. Akyol A., Kiylioglu N., Kadikoylu G., et al. Iron deficiency anemia and restless legs syndrome: is there an electrophysiological abnormality?. Clin Neurol Neurosurg 2003, 106:23-27.
116. Lee K., Zaffke M., Baratte-Beebe K. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. J Womens Health Gend Based Med 2001, 10(4):335-341.
117. Tunc T., Karadag Y., Dogulu F., et al. Predisposing factors of restless legs syndrome in pregnancy. Mov Disord 2007, 22(5):627-631.
118. Dzaja A., Wehrle R., Lancel M., et al. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep 2009, 32(2):169-174.
119. Burchell B.J., Allen R.P., Miller J.K., et al. RLS and blood donation. Sleep Med 2009, 10(8):844-849.
120. Becker P.M. Bleed less than 3: RLS and blood donation. Sleep Med 2009, 10(8):820-821.
121. Berger K., von Eckardstein A., Trenkwalder C., et al. Iron metabolism and the risk of restless legs syndrome in an elderly general population-the MEMO study. J Neurol 2002, 249:1195-1199.
122. Earley C., Heckler D., Allen R. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004, 5:231-235.
123. Earley C.J., Horska A., Mohamed M.A., et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009, 10(2):206-211.
124. Grote L., Leissner L., Hedner J., et al. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009, 24(10):1445-1452.
125. Aul E.A., Davis B.J., Rodnitzky R.L. The importance of formal serum iron studies in the assessment of restless legs syndrome. Neurology 1998, 51(3):912.
126. Freeman A., Rye D. Dopamine in behavioral state control. The neurochemistry of sleep and wakefulness 2008, 179-223. Cambridge University Press, Cambridge (United Kingdom). C. Sinton, P. Perumal, J. Monti (Eds.).
127. Ramsey A., Hillas P., Fitzpatrick P. Characterization of the active site iron in tyrosine hydroxylase redox states of the iron. J Biol Chem 1996, 271:24395-24400.
128. Nagatsu I. Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem 1995, 30:15-35.
129. Nelson C., Erikson K., Pinero D.J., et al. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr 1997, 127(12):2282-2288.
130. Bianco L.E., Wiesinger J., Earley C.J., et al. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. J Neurochem 2008, 106(1):205-215.
131. Bianco L., Unger E., Earley C., et al. Iron deficiency alters the day-night variation in monoamine levels in mice. Chronobiol Int 2009, 26(3):447-463.
132. Hue G.E., Decker M.J., Solomon I.G., et al. Increased wakefulness and hyper-responsivity to novel environments in mice lacking functional dopamine D3 receptors. Soc Neurosci 2003, 616:16.
133. Beckford G. The functional organization and behavioral relevance of the A11 hypothalamospinal dopaminergic system 2008, Emory, Atlanta (GA).
134. Allen R.P., Connor J.R., Hyland K., et al. Abnormally increased CSF 3-ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009, 10(1):123-128.
135. Connor J.R., Wang X.S., Allen R.P., et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009, 132(Pt 9):2403-2412.
136. Perez-Diaz H., Iranzo A., Rye D.B., et al. Restless abdomen: a phenotypic variant of restless legs syndrome. Neurology 2011, 77(13):1283-1286.
137. Benes H., von Eye A., Kohnen R. Empirical evaluation of the accuracy of diagnostic criteria for restless legs syndrome. Sleep Med 2009, 10(5):524-530.
138. Stiasny-Kolster K., Kohnen R., Moller J.C., et al. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord 2006, 21(9):1333-1339.
139. Salin-Pascual R., Galicia-Polo L., Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997, 58(8):348-350.
140. Yang C., White D.P., Winkelman J.W. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005, 58(6):510-514.
141. Page R.L., Ruscin J.M., Bainbridge J.L., et al. Restless legs syndrome induced by escitalopram: case report and review of the literature. Pharmacotherapy 2008, 28(2):271-280.
142. Rottach K.G., Schaner B.M., Kirch M.H., et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008, 43(1):70-75.
143. Fox E.J., Villanueva R., Schutta H.S. Myoclonus following spinal anesthesia. Neurology 1979, 29(3):379-380.
144. Lee M.S., Lyoo C.H., Kim W.C., et al. Periodic bursts of rhythmic dyskinesia associated with spinal anesthesia. Mov Disord 1997, 12(5):816-817.
145. Nadkarni A.V., Tondare A.S. Localized clonic convulsions after spinal anesthesia with lidocaine and epinephrine. Anesth Analg 1982, 61(11):945-947.
146. Watanabe S., Sakai K., Ono Y., et al. Alternating periodic leg movement induced by spinal anesthesia in an elderly male. Anesth Analg 1987, 66(10):1031-1032.
147. Hogl B., Frauscher B., Seppi K., et al. Transient restless legs syndrome after spinal anesthesia: a prospective study. Neurology 2002, 59(11):1705-1707.
148. Montplaisir J., Boucher S., Poirier G., et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997, 12:61-65.
149. Bixler E., Kales A., Vela-Bueno A., et al. Nocturnal myoclonus and nocturnal myoclonic activity in the normal population. Res Commun Chem Pathol Pharmacol 1982, 36(1):129-140.
150. Scofield H., Roth T., Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep 2008, 31(9):1221-1227.
151. Allen R., Earley C. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19:205-213.
152. Picchietti M.A., Picchietti D.L. Restless legs syndrome and periodic limb movement disorder in children and adolescents. Semin Pediatr Neurol 2008, 15(2):91-99.
153. Santamaria J., Iranzo A., Tolosa E. Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep. Sleep Med 2003, 4:153-155.
154. Walters A., Picchietti D., Hening W., et al. Variable expressivity in familial restless legs syndrome. Arch Neurol 1990, 47:1219-1220.
155. Birinyi P.V., Allen R.P., Hening W., et al. Undiagnosed individuals with first-degree relatives with restless legs syndrome have increased periodic limb movements. Sleep Med 2006, 7(6):480-485.
156. O'Brien L.M., Holbrook C.R., Faye Jones V., et al. Ethnic difference in periodic limb movements in children. Sleep Med 2007, 8(3):240-246. [see comment].
157. Michaud M., Soucy J., Chabli A., et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002, 249:164-170.
158. Rye D., Bliwise D., Iranzo A., et al. A novel 2-step diagnostic approach for RLS disease classification. Sleep 2004, 27(Suppl S):306-307.
159. Sforza E., Johannes M., Claudio B. The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med 2005, 6(5):407-413. [see comment].
160. Tuisku K., Holi M., Wahlbeck K., et al. Quantitative rest activity in ambulatory monitoring as a physiological marker of restless legs syndrome: a controlled study. Mov Disord 2003, 18:442-448.
161. Tuisku K., Holi M., Wahlbeck K., et al. Actometry in measuring the symptom severity of restless legs syndrome. Eur J Neurol 2005, 12:385-387.
162. Rye D., Allen R., Carson S., et al. Ropinirole decreases bedtime periodic leg movements in patients with RLS: results of a 12-week US study. Sleep 2005, 28(Suppl S):A270.
163. Hening W., Walters A., Kavey N., et al. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology 1986, 36:1363-1366.
164. Hening W.A. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007, 120(1 Suppl 1):S22-S27.
165. Silber M., Ehrenberg B., Allen R., et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004, 79:916-922.
166. Hornyak M., Feige B., Riemann D., et al. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. Sleep Med Rev 2006, 10(3):169-177.
167. Urbano M.R., Ware J.C. Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin Pharmacol 2008, 28(6):704-705.
168. Kim S., Shin I., Kim J., et al. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol 2005, 28(6):298-301.
169. Lee J., Erdos J., Wilkoosz M., et al. Bupropion as a possible treatment option for restless legs syndrome. Ann Pharmacother 2009, 43(2):370-374.
170. Smith H.S., Dhingra R., Ryckewaert L., et al. Proton pump inhibitors and pain. Pain Physician 2009, 12(6):1013-1023.
171. Numata Y., Kato T., Nagatsu T., et al. Effects of stereochemical structures of tetrahydrobiopterin on tyrosine hydroxylase. Biochim Biophys Acta 1977, 480(1):104-112.
172. Botez M., Lambert B. Folate deficiency and restless legs syndrome in pregnancy. N Engl J Med 1977, 297(12):670.
173. O'Keeffe S., Gavin K., Lavan J. Iron status and restless legs syndrome in the elderly. Age Ageing 1994, 23:200-203.
174. Bachmann C., Guth N., Helmshmied K., et al. Homocysteine in restless legs syndrome. Sleep Med 2008, 9(4):388-392.
175. Davis B.J., Rajput A., Rajput M.L., et al. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000, 43(2):70-75.
176. Wang J., O'Reilly B., Venkataraman R., et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med 2009, 10(9):973-975.
177. Morgan J.C., Ames M., Sethi K.D. Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin. J Neurol Neurosurg Psychiatr 2008, 79(8):964-965.
178. Trenkwalder C., Hogl B., Benes H., et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008, 9(5):572-574.
179. Umbreit J. Iron deficiency: a concise review. Am J Hematol 2005, 78(3):225-231.
180. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol 2004, 76(1):74-78.
181. Sloand J., Shelly M., Feigin A., et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
182. Becker P., Patrick F., Dubrava S., et al. Effect of pregabalin on sleep disturbances in patients with restless legs syndrome (Willis-Ekbom disease). Sleep 2012, 35:A257.
183. Happe S., Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004, 18(1):27-36.
184. Fulda S., Wetter T.C. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008, 131(Pt 4):902-917.
185. Diederich N.J., Goetz C.G. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 2008, 71(9):677-684.
186. Montplaisir J., Nicolas A., Denesle R., et al. Restless legs syndrome improved by pramipexole: a double-blind randomized study. Neurology 1999, 52:938-943.
187. Montplaisir J., Denesle R., Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000, 7(Suppl 1):27-31.
188. Winkelman J.W., Sethi K.D., Kushida C.A., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006, 67(6):1034-1039.
189. Ferini-Strambi L., Aarskog D., Partinen M., et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008, 9:874-881.
190. Partinen M., Hirvonen K., Jama L., et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study. Sleep Med 2006, 7(5):407-417.
191. Trenkwalder C., Hening W.A., Montagna P., et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008, 23(16):2267-2302.
192. Adler C.H., Hauser R.A., Sethi K., et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2004, 62(8):1405-1407.
193. Walters A.S., Ondo W.G., Dreykluft T., et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004, 19(12):1414-1423.
194. Allen R., Becker P.M., Bogan R., et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004, 27(5):907-914.
195. Bliwise D.L., Freeman A., Ingram C.D., et al. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005, 6(2):141-147.
196. Bogan R.K., Fry J.M., Schmidt M.H., et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006, 81(1):17-27.
197. Quilici S., Abrams K., Nicolas A., et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008, 9(7):715-726.
198. Stiasny-Kolster K., Benes H., Peglau I., et al. Effective cabergoline treatment in idiopathic restless legs syndrome (RLS): a randomized, double-blind, placebo-controlled, multicenter dose-finding study followed by an open long-term extension. Neurology 2004, 63(12):2272-2279.
199. Benes H., Heinrich C.R., Ueberall M.A., et al. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004, 27(4):674-682.
200. Oertel W.H., Benes H., Bodenschatz R., et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006, 67(6):1040-1046.
201. Trenkwalder C., Benes H., Grote L., et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007, 22(5):696-703.
202. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356(1):39-46.
203. Benes H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 2006, 7(1):31-35.
204. Stiasny-Kolster K., Kohnen R., Schollmayer E., et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004, 19(12):1432-1438.
205. Oertel W.H., Benes H., Garcia-Borreguero D., et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010, 11(9):848-856.
206. Oertel W.H., Benes H., Garcia-Borreguero D., et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008, 9:865-873.
207. Hening W.A., Allen R.P., Ondo W.G., et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010, 25(11):1675-1683.
208. Oertel W., Trenkwalder C., Benes H., et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011, 10(8):710-720.
209. Benes H., Garcia-Borreguero D., Ferini-Strambi L., et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 2012, 13(6):589-597.
210. Paulus W., Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006, 5(10):878-886.
211. Sommer M., Bachmann C.G., Liebetanz K.M., et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007, 115(5):347-350.
212. Allen R., Chen C., Soaita A., et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010, 11(6):512-519.
213. Garcia-Borreguero D., Larrosa O., Williams A.M., et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010, 74(23):1897-1904.
214. Kushida C., Ellenbogen A., Becker P., et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of XP13512 1200 mg in patients with restless legs syndrome. Neurology 2008, 70(11):A409.
215. Kushida C.A., Walters A.S., Becker P., et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009, 32(2):159-168.
216. Winkelman J.W., Bogan R.K., Schmidt M.H., et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011, 26(11):2065-2072.
217. Lee D.O., Ziman R.B., Perkins A.T., et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011, 7(3):282-292.
218. Walters A.S., Winkelmann J., Trenkwalder C., et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001, 16(6):1105-1109.
219. Wagner M.L., Walters A.S., Coleman R.G., et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996, 19(1):52-58.
220. Lettieri C.J., Eliasson A.H. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest 2009, 135(1):74-80.
221. Hayes C.A., Kingsley J.R., Hamby K.R., et al. The effect of endovenous laser ablation on restless legs syndrome. Phlebology 2008, 23(3):112-117.
222. Cui Y., Wang Y., Liu Z. Acupuncture for restless legs syndrome. Cochrane Database Syst Rev 2008, (4). CD006457.
223. Aukerman M.M., Aukerman D., Bayard M., et al. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2006, 19(5):487-493.
224. Kavanagh D., Siddiqui S., Geddes C.C. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004, 43(5):763-771.
225. Winkelmann J., Stautner A., Samtleben W., et al. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002, 17(5):1072-1076.
226. Molnar M.Z., Novak M., Ambrus C., et al. Restless legs syndrome in patients after renal transplantation. Am J Kidney Dis 2005, 45(2):388-396.
227. Miranda M., Kagi M., Fabres L., et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004, 62(5):831-832.
228. Bartell S., Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med 2006, 2(2):187-188.
229. Djokanovic N., Garcia-Bournissen F., Koren G. Medications for restless legs syndrome in pregnancy. J Obstet Gynaecol Can 2008, 30(6):505-507.
230. Guilleminault C., Cetel M., Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993, 43(2):445.
231. Garcia-Borreguero D., Allen R.P., Kohnen R., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association Of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8(5):520-530.
232. Earley C.J., Allen R.P. Restless legs syndrome augmentation associated with tramadol. Sleep Med 2006, 7(7):592-593.
233. Garcia-Borreguero D., Kohnen R., Hogl B., et al. Validation of the Augmentation Severity Rating Scale (ASRS). Sleep Med 2007, 8:455-463.
234. Garcia-Borreguero D., Allen R.P., Benes H., et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007, 22(Suppl 18):S476-S484.
235. Ondo W., Romanyshyn J., Vuong K., et al. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004, 61:1393-1397.
236. Ondo W.G. Methadone for refractory restless legs syndrome. Mov Disord 2005, 20(3):345-348.
237. Kurlan R., Richard I., Deeley C. Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. J Gen Intern Med 2006, 21(12):C1-C4.
238. Tippmann-Peikert M., Park J.G., Boeve B.F., et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68(4):301-303.
239. Quickfall J., Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007, 13(8):535-536.
240. Evans A.H., Stegeman J.R. Punding in patients on dopamine agonists for restless leg syndrome. Mov Disord 2009, 24(1):140-141.
241. Salas R.E., Allen R.P., Earley C.J., et al. A case of compulsive behaviors observed in a restless legs syndrome patient treated with a dopamine agonist. Sleep 2009, 32(5):587-588.
242. Kolla B.P., Mansukhani M.P., Barraza R., et al. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling. Psychosomatics 2010, 51(3):271-273.
243. Driver-Dunckley E.D., Noble B.N., Hentz J.G., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007, 30(5):249-255.
244. Pourcher E., Remillard S., Cohen H. Compulsive habits in restless legs syndrome patients under dopaminergic treatment. J Neurol Sci 2010, 290(1-2):52-56.
245. Ondo W.G., Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008, 14(1):28-32.
246. Cornelius J., Tippmann-Piekert M., Slocumb N., et al. Impulse control disorders with use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010, 33(1):81-87.
247. Voon V., Thomsen T., Miyasaki J.M., et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007, 64(2):212-216.
248. Potenza M.N., Voon V., Weintraub D. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 2007, 3(12):664-672.
249. Bayard S., Yu H., Langenier M.C., et al. Decision making in restless legs syndrome. Mov Disord 2010, 25(15):2634-2640.
250. Chesson A.L., Wise M., Davila D., et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999, 22(7):961-968.
251. Trotti L.M., Bhadriraju S., Rye D.B. An update on the pathophysiology and genetics of restless legs syndrome. Curr Neurol Neurosci Rep 2008, 8(4):281-287.